Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAP mRNA Vaccine in Advanced Malignant Solid Tumors
NCT07363369Phase 1Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 1, open-label trial of BNT142 in Advanced Malignant Solid Neoplasm (AMSN) (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose-limiting toxicities at 1 year and Treatment-related adverse events at 1 year. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
BNT142
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT07363369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363369.